Navigation Links
Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Date:3/26/2013

i>and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)(in thousands except share and per share data)Three Months Ended Dec 31,Twelve Months Ended Dec 31,2012201120122011OPERATING EXPENSE:  Research and development

$
7,089$
26,832$
49,219$
85,281  General and administrative

1,0001,5976,7157,857Total operating expense

8,08928,42955,93493,138LOSS FROM OPERATIONS:

(8,089)(28,429)(55,934)(93,138)OTHER (EXPENSE)/INCOME:Other (expense) income

(27)185(111)606Interest expense

(797)(912)(3,354)(2,803)Total other income (expense)

(824)(727)(3,465)(2,197)NET LOSS

$  (8,913)$   (29,156)$  (59,399)$   (95,335)Net loss per share--basic and diluted

$
(0.11)$
(0.71)$
(1.03)$
(2.55) Weighted-average number of shares used in per share calculation-- basic and diluted

79,120,94040,916,66657,803,49137,417,775 

 ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)(in thousands except share amounts)December 31,
2012December 31,
2011Cash and cash equivalents

$
9,431$
5,624Short term investments

$
5,322$
,746Total assets

$
26,445$
9,493Total current liabilities, excluding current portion of notes payable

$
9,421$
26,078Total notes payable

$
20,550$
24,331Deficit accumulated during development stage

$  (260,378)$  (200,979)Total sh
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
2. Anthera to Report Second Quarter 2012 Financial Results
3. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
4. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
5. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
6. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
7. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
8. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
9. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
10. AVANIR Pharmaceuticals To participate in two conferences in March
11. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Empowering biomedical researchers with ... Cubresa Inc. today announced its MR Compatible Small ... PET Scanner uses silicon photomultiplier detector technology, so ... machines from manufacturers like Bruker and Agilent,” said ... Canada. “This enables simultaneous PET and MRI data ...
(Date:5/27/2015)... , May 27, 2015  US-Australian drug discovery and ... announced today that it will present at the Brain Tumor ... on May 29, 2015. The venue is the ... Manhattan . The Brain Tumor Biotech ... the pharmaceutical industry and the investment community to promote innovative ...
(Date:5/26/2015)... Miami (PRWEB) May 26, 2015 ... a new stem cells clinic in Buenos Aires, Argentina. ... a renowned critical care specialist. Pastrana has assembled a ... endocrinology and orthopedics in her state-of-the-art Puerto Madero office. ... operate phase I to phase IV clinical studies in ...
(Date:5/26/2015)... 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... CEO, will provide an update on the progress of Sangamo,s ... the company,s business strategy at 1:30pm ET on Monday, June ... conference is being held in New York, NY ... and may be accessed via a link on the Sangamo ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... Tengion, Inc. (Nasdaq: TNGN ), a leader ... definitive agreements with certain investors in connection with a PIPE ... of 1933, as amended.  Medtronic (NYSE: MDT ), ... and, as part of its investment, secured a right of ...
... Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN ... eduction f or A dults R eceiving ... Overlake Hospital Medical Center in Bellevue and other major hospital ... determine a personalized warfarin dose for individual patients to reduce ...
... 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... for the third quarter and first nine months of fiscal ... Quarter of Fiscal 2011 ...
Cached Biology Technology:Tengion Announces Pricing of $31.4 Million Private Placement 2Tengion Announces Pricing of $31.4 Million Private Placement 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... today announced that members of the executive management team will ... 43rd Annual Technology, Media and Telecom Conference Date: May ... in Boston, MA Cowen ... 2015 Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... December 17th, 2013 - Eurofins Medigenomix, a part of ... Orion Diagnostica Oy, an in vitro diagnostics company specialising ... systems, announced that they have signed a co-exclusive technology ... for the SIBA isothermal nucleic acid detection technology in ...
... birth to live young, rather than laid eggs, and over ... reproductive mode, according to research published in print in ... unusual and controversial finding, and a major overturn of an ... Assistant Professor of Biology in the Columbian College of Arts ...
... controlling the temperature of silica rods as they grow, ... Laboratory could be setting the stage for advances in ... and more. The goal of fabricating fixed-size one-dimensional ... diameter during growth has long eluded scientists. Now, Panos ...
Cached Biology News:Ancestor of snakes, lizards likely gave birth to live young 2ORNL devises recipe to fine-tune diameter of silica rods 2
... This thin foil heat sealing material ... pressure from a screw down heated ... is a useful method for sample ... over the existing seal. Ideal for ...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
... Western Blot Strong Antibody Stripping Solution is ... blots that have been developed with chemiluminescence ... is not recommended for stripping colorimetric substrates ... not possible to effectively remove substrates that ...
...
Biology Products: